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context: Myotonic dystrophies (DM) are dominantly inherited muscle disorders charac-
terized by myotonia, muscle weakness, and wasting. The reasons for sarcopenia in DMs 
are uncleared and multiple factors are involved. Irisin, a positive hormone regulator of 
muscle growth and bone, may play a role.
Objectives: To investigate (1) circulating irisin in a series of DM1 and DM2 male patients 
compared with healthy controls and (2) the relationships between irisin and anthropo-
metric, metabolic and hormonal parameters.
Design and study participants: This is a cross-sectional study. Fasting blood samples 
for glucometabolic, gonadic, bone markers, and irisin were collected from 28 ambulatory 
DM1, 10 DM2, and 23 age-matched healthy male subjects. Body composition and bone 
mineralization [bone mineral density (BMD)] were measured by DEXA. Echocardiographic 
assessment and visceral adiposity, namely, liver and epicardial fat, were investigated by 
ultrasound. Irisin released from cultured myotubes derived from 3 DM1, 3 DM2, and 3 
healthy donors was assayed.
results: Plasma irisin levels were definitely lower in both DM1 and DM2 patients than 
in controls with no difference between DM1 and DM2. Irisin released from DM1 and 
DM2 myotubes was similar to that released from myotubes of the non-DM donors, 
though diabetic DM2 myotubes released more irisin than DM1 myotubes. There was 
no correlation between irisin and muscle strength or lean mass in both DM1 and DM2 
patients. In DM1 patients, plasma irisin levels correlated negatively with oxygen con-
sumption and positively with insulin resistance, while in DM2 patients plasma irisin 
levels positively correlated with fat mass at arms and legs levels. No correlation with 
visceral fat, left ventricular mass, and gonadal hormones could be detected. In both 
DM1 and DM2 patients, legs BMD parameters positively correlated with plasma irisin 
levels.
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conclusion: Plasma irisin is reduced in both DM1 and DM2 male patients likely reflect-
ing muscle mass reduction. Moreover, insulin resistance may contribute to modulation of 
plasma irisin in DM1 patients. The irisin-mediated cross talk muscle–adipose tissue–bone 
may be active also in the male myotonic dystrophies’ model.
Keywords: myotonic distrophies, myotubes, irisin, fat mass, insulin resistance, bone density
both fluorescence in situ hybridization on muscle frozen sections 
using a (CAGG) 5 probe and by Southern blot-based kit (15).
All the DM patients were ambulant. Patients aged <18 and 
>70 years, with heart, kidney, or liver failure, previous or current 
corticosteroid treatment, hormone replacement, anti-epileptic 
therapy were excluded. All the participants gave their written 
informed consent and the local ethical committee approved 
the study protocol. The study complied with the Declaration of 
Helsinki.
clinical, Biochemical, and hormonal 
assessment
Anthropometric measurements were investigated in all patients 
and healthy controls, including height, weight, and body mass 
index. Abdominal fat was evaluated as waist circumference, 
liver fat, and epicardic fat were evaluated by ultrasound imag-
ing, as previously described (16). Calculation of resting energy 
expenditure was performed by indirect calorimetry (VMAX 
Encore, VIASYS Healthcare, Inc., Yorba Linda, CA, USA). All 
DM patients were studied by routine ultrasound cardiac imaging 
for the evaluation of cardiac mass. Muscle strength was deter-
mined according to the modified 5-point MRC scale (Medical 
Research Council) in the upper and lower limbs for a total of 150 
maximum score (Medical Research). Stage of the disease for DM1 
patients was defined using Muscular Impairment Rating Scale 
(17). Mobility was assessed according to Rivermead Mobility 
Index (RMI) (18). A subgroup of 15 DM1 and 10 DM2 patients 
was further investigated by dual-energy X ray absorptiometry 
(DEXA) total body scanner for regional body composition and 
for the measurement of segmental bone mineral density (BMD) 
using a Hologic densitometer. Regarding the lower and upper 
limbs, we considered a mean value of the BMDs measured at left 
and right limbs. Participants were scanned in light clothing, while 
lying flat on their backs with arms at their sides.
Venous blood samples were collected after an overnight fasting 
in all patients for determination of glucose, total and HDL choles-
terol, triglycerides, albumin, HbA1c levels according to routinely 
used laboratory kits. To assess calcium and bone metabolism, 
calcium, phosphate, creatinine albumin and alkaline phosphatase 
were measured according to routinely used laboratory kits. Serum 
PTH levels were determined by ElectroChemiLuminescence on 
an Elecsys 2010 (Roche Diagnostics, Mannheim, Germany) and 
serum 25OHvitamin D (25OHD) was measured by a chemilu-
minescent assay (LIAISON® test, DiaSorin Inc., Stillwater, MN, 
USA). Gonadic function was assessed by measurement of serum 
total testosterone (T), SHBG, 17βestradiol, LH, and FSH levels by 
ECLIA assays (Roche Diagnostic, Milan, Italy). Free testosterone 
(free T) was calculated from T, SHBG and albumin according 
inTrODUcTiOn
Skeletal muscle is emerging as an endocrine organ. A number 
of biological active molecules are expressed and released from 
muscle cells known as myokines (1). Among them, irisin, the 
cleaved fragment of the transmembrane protein type-III domain 
containing protein 5 (FNDC5), was shown to induce adipocyte 
browning. Irisin acts on subcutaneous adipose tissue increasing 
thermogenesis and energy expenditure, therefore granting pro-
tection against obesity and insulin resistance (2). Moreover, irisin 
stimulates myogenesis (3). The circulating 22 kDa form of irisin 
has been quantitated in human plasma by mass spectrometry (4, 
5). Plasma irisin levels are increased in mice and humans after 
short-term exercise (6), and it is emerging as a sensitive marker 
for muscle weakness and atrophy (7).
Myotonic dystrophies (DM) are multisystemic disorders 
affecting skeletal muscles, with myotonia, muscle weakness and 
atrophy (8). Myotonic dystrophy type 1 (DM1) is the most com-
mon adult form of muscular dystrophy, while myotonic dystro-
phy type 2 (DM2) is rare. DM1 is due to a CTG repeat expansion 
in the DMPK gene on chromosome 19q13, while an expansion 
of CCTG repeat in the CNBP gene on chromosome 3q21 causes 
DM2 (9). Multiple organs are involved including pancreas, liver, 
gonads, thyroid, and bone. Insulin resistance, liver steatosis, 
hypogonadism, goiter, and vitamin D deficiency are common 
features. Sarcopenia is multifactorial, though it is likely that the 
endocrine abnormalities play a role (10). At the skeletal muscle 
level, still there is no mechanistic explanation for the observed 
muscle weakness and atrophy in DM patients (11–13).
Here, we tested the hypothesis that DM-related myopathic 
changes of skeletal muscle cells might impair their endocrine 
function, therefore contributing to the non-muscle phenotype 
of both DM conditions, namely, insulin resistance, lipid profile 
alterations, visceral fat distribution, and bone mineral impair-
ment. Therefore, we investigated the circulating and myotubes-
released irisin in DM patients compared with non-DM donors.
MaTerials anD MeThODs
study Population
Twenty-eight male patients (44.7  ±  11.6  years; mean  ±  SD) 
affected with adult-onset DM1, 10 male patients affected with 
DM2 (56.7 ± 9.3 years) and 23 age-matched, physically active, 
male healthy control subjects (49.5 ± 8.3 years) were consecu-
tively enrolled. We focused the study in male patients to avoid 
gender differences in the gonadal hormonal status. Clinical and 
bioptic diagnosis of DM1 was genetically confirmed by Southern 
blot-based kit (14). Clinical diagnosis of DM2 was confirmed by 
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to the method of Vermeulen et  al. (19). Serum anti-Müllerian 
hormone (AMH) and inhibin B concentrations were measured 
by a II generation ELISA kit (Beckman Coulter, Brea, CA, USA).
Plasma irisin levels were measured by an irisin/FNDC5 
(extracellular domain molecule: epitope 16-127) assay kit 
(Phoenix Pharmaceuticals, CA, USA; sensitivity 1.3 ng/ml, range 
0.1–1,000 ng/ml and linear range between 1.29 and 27.5 ng/ml) 
(20, 21). Antibody used in this kit recognizes recombinant full 
length irisin, irisin (42–112) (100%) and recombinant FNDC5, 
isoform 4 (9%), but not the irisin precursor C-terminal 48-mer 
FNDC5 (165–212) and irisin (42–95). Irisin concentrations in 
conditioned media were determined using the same kit.
Primary human skeletal Muscle cell 
cultures
Human satellite cells were isolated from biceps brachii muscle 
biopsies from 3 DM1, 3 DM2 patients and from three subject with 
no sign of neuromuscular disease used as controls, as previously 
described (22). Myoblasts were grown in HAM’s F10 medium 
(Sigma-Aldrich) supplemented with 15% FBS (Euroclone), 
0.5 mg/mL albumin from bovine serum (BSA, Sigma-Aldrich), 
0.5 mg/mL fetuin (Sigma-Aldrich), 0.39 µg/mL dexamethasone, 
10 ng/mL epidermal growth factor, 0.05 mg/mL insulin, 3 mg/
mL glucose, 100 U/mL penicillin, and 100 µg/mL streptomycin 
(proliferative medium). For this study, cells from DM and con-
trol patients were plated at a density of 60,000 cells per 35 mm 
dishes. When myoblasts reached 80% of confluence, proliferative 
medium was replaced by differentiative medium (DMEM/High 
Glucose supplemented with 7% FBS, in presence of 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 0.01 mg/mL insulin) to 
allow myoblasts fusion. Myotubes and conditioned media were 
harvested after 5 days of differentiation (T5) and irisin concentra-
tion was determined after 6 h of incubation in serum and fetuin-
free conditioned media.
immunofluorescence, Myogenic Purity, 
and Differentiative capability
Immunofluorescence has been performed on proliferating 
myoblasts and on T5 myotubes Muscle cell cultures were fixed 
in 4% paraformaldehyde for 15 min at 4°C. After fixation, cells 
were washed several times in PBS and then permeabilized in 0.4% 
Triton X 100 in PBS for 5 min. After washing in PBS, non-specific 
binding sites were blocked with NGS (Dako-Cytomation) at a 
dilution 1:20 in PBS + 2% BSA for 20 min at room temperature. 
Myoblast and T5 myotubes were then incubated, respectively, 
with a primary antibody mouse monoclonal anti-desmin (CD33, 
Dako, 1:100 in PBS +  2%BSA) and a mouse monoclonal anti 
MHC-fast (Sigma- Aldrich, 1:600 in PBS + 2%BSA) for 1 h at 
room temperature. After washing in PBS 3× 5  min, cells were 
incubated for 1 h at room temperature with secondary antibodies 
(goat anti mouse Alexa 488-labeled; Molecular Probes, Eugene, 
OR, USA; 1:400 in PBS + 2%BSA). After washing in PBS 3× 5 min, 
nuclei were stained with 165 nM 4,6-diamidino-2-phenylindole. 
Cells were finally mounted with Mowiol and examined using 
a fluorescence microscope. Myogenic purity was evaluated on 
desmin immunostained myoblasts. The percentage of desmin 
positive myoblasts was calculated as the number of positive cells 
vs the total number of cells observed. Differentiative capability 
was evaluated as fusion index on T5 myotubes MHC-fast myosin 
immunostained. Fusion index was determined as number of 
nuclei in multinucleated myotubes expressed as a percentage of 
the total number of nuclei. At least 100 nuclei were counted in at 
least 10 different optical fields randomly chosen.
statistical analysis
Continuous variable are presented as mean  ±  SD; normal 
distribution of continuous variables was tested: plasma irisin, 
insulin and HOMA-IR levels failed to pass normality test, 
therefore irisin values were normalized by log2 transformation 
for further statistical analysis. Simple correlation analyses were 
performed using Pearson correlation. Categorical data are 
presented as percentages. Fisher exact test or χ2 test were also 
used to compare the categorical variables among the different 
groups. Groups were compared using T test for normal vari-
ables or Mann–Whitney U-test for non-parametric variables. 
A P value less than 0.05 was considered significant. Statistical 
analysis was performed using Prism 6.0.
resUlTs
circulating irisin in DM1 and  
DM2 Male Patients
At rest, plasma irisin levels detected in male healthy physically 
active subjects ranged from 1.8 to 5.6 ng/mL [3.0 (2.4–3.5) ng/mL, 
median, range interquartile]. Plasma irisin levels in DM1 patients 
ranged 0.68 to 2.52 ng/mL; median plasma irisin level in DM1 
patients was 1.4 (1.1–1.5) ng/mL, and it was significantly lower 
than the median level detected in healthy controls (P < 0.0001) 
(Figure 1A). Plasma irisin levels detected in patients with DM1 
did not differ significantly from levels detected in patients with 
DM2 [1.1 (1.0–1.5) ng/ml], which were definitely lower than 
levels detected in controls (Figure 1A).
irisin release from Myotubes of DM1  
and DM2 Male Patients
All starting cell populations used in this study had a myogenic purity 
higher than 80% (data not shown). All cultured myotube prepara-
tions from DM1, DM2 patients and control donors showed a fusion 
index of about 60% (data not shown). The DM2 myotubes were 
from patients with diet-treated diabetes, while both DM1 and con-
trol donors myotubes were from normoglycemic patients. Cultured 
myotubes derived from DM patients’ biopsies released detectable 
amounts of irisin in the medium (Figure 1B). Irisin released from 
DM1 myotubes was significantly lower than that released from the 
DM2 myotubes (0.22 ± 0.07 vs 0.41 ± 0.07 ng/ml; P = 0.03), though 
they both did not significantly differ from that released from healthy 
controls myotubes (0.33 ± 0.18 ng/ml; Figure 1B).
correlations between Plasma irisin levels 
and Metabolic Parameters in DM1 Patients
There was any significant correlation between plasma irisin levels 
and the age of patients at time of clinical evaluation or with the 
FigUre 1 | (a) Plasma irisin levels in DM1, DM2 male patients and 
age-matched, physically active, male healthy controls. *P < 0.0001 by 
ANOVA. (B) Surnatant irisin levels from 5 days-differentiated myotubes 
derived from DM1, DM2 patients and healthy controls; *P = 0.03.
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entity of triplet expansions. Any correlation could be detected 
between plasma irisin and parameters of muscle strength and 
performance, namely MRC and RMI (Table 1). Both total and 
segmental lean masses did not show any significant correlation 
with plasma irisin levels. Cardiac muscle mass has also been 
evaluated in DM patients by measurement of left ventricular 
mass by routine echocardiography (Table S1 in Supplementary 
Material): plasma irisin levels did not show any significant corre-
lation with the left ventricular mass. Moreover, all the parameters 
describing fat mass (Table  1) were not correlated with irisin 
levels in DM1 patients, while a negative correlation was detected 
between plasma irisin levels and VO2 consumption (r = −0.429, 
P = 0.029).
In normoglycemic DM1 patients (n  =  27), plasma irisin 
levels positively correlated with insulin (r =  0.457; P =  0.017; 
Figure  2A) and HOMA-IR (r =  0.428; P =  0.026; Figure  2B). 
Any significant correlation was detected between plasma irisin 
and serum glucose as well as with lipid profile, namely serum total 
cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides 
levels (Table  1). Similarly, there was any correlation with both 
Sertoli and Leydig cell hormones, namely, serum total and free 
testosterone, serum inhibin B and AMH levels (Table 1).
Plasma irisin levels were positively correlated with serum 
25OHD in DM1 patients (r =  0.451; P =  0.018); indeed, after 
adjustment for the fat mass, the correlation was no longer signifi-
cant suggesting that it is mediated by the known correlation with 
the fat mass (23). Finally, in normoglycemic DM1 patients plasma 
irisin positively correlated with pelvis BMD (r = 0.622, P = 0.041) 
and mean legs BMD (r = 0.569, P = 0.045) (Table 2).
correlations between Plasma irisin levels 
and Metabolic Parameters in DM2 
Patients
Plasma irisin levels in DM2 patients did not correlate with age, 
and parameters of muscle strength and performance, MRC and 
RMI, as observed in DM1 patients (Table 1). Though total and 
segmental lean masses, as well as cardiac left ventricular mass, 
did not show any significant correlation with plasma irisin levels 
in DM2 patients (Table 1; Table S1 in Supplementary Material), 
total fat mass (Figure 3A), and fat mass at arms and legs levels 
positively correlated with plasma irisin levels (Table 3).
At variance with DM1 patients, any significant correlation 
could be detected with parameters of insulin resistance and glu-
cose metabolism as well as with lipid profile, gonadal function, 
and vitamin D status in normoglycemic DM2 patients (Table 1). 
Plasma irisin positively correlated with both T-score (r = 0.679, 
P  =  0.031; Figure  3B and Table  2) and Z-score (r  =  0.719, 
P = 0.019) at femur neck level in DM2 patients. Indeed, consider-
ing normoglycemic DM2 patients (n = 6) in order to exclude the 
effect of diabetes, the correlation could not be further detected, 
likely due to the small sample size.
DiscUssiOn
Myokines modulate processes related to energy metabolism and 
muscle regenerative capacity in active muscle; moreover, they 
modulate plasticity of other organs and tissues as a part of the 
adaptive response to acute and/or regular exercise. The discovery 
of irisin raised great interest in the scientific community for its 
role as mediator of the cross talk between muscle and fat (24) and, 
more recently, between muscle and bone (25, 26). Nonetheless, 
some Authors claimed that the poor antibodies specificity against 
irisin give artifacts in measuring human irisin; indeed, by using 
an unbiased assay, human irisin has been demonstrated and 
quantitated in human plasma samples (5). The ELISA assays used 
in the present study detected irisin concentrations in the plasma 
samples from the male healthy controls similar to those detected 
by tandem mass spectrometry in sedentary males (5).
Though the role of irisin in clinical diseases is almost unknown, 
its functional characteristics suggest it may be involved in muscle 
dystrophies. Patients with DM1 and DM2 have muscle wasting 
and sarcopenia, involving proximal or distal segments of the 
extremities, respectively. In the present study, we first investigated 
TaBle 1 | Clinical, anthropometric, hormone, and metabolic parameters in DM1, DM2, patients, and healthy controls.
Parameters DM1 (n = 28) DM2 (n = 10) P-value* controls (n = 23)
Age 44.7 ± 11.5 56.7 ± 9.3 0.005 45.6 ± 14.5
BMI (kg/m2) 25.1 ± 4.1 26.8 ± 4.4 0.267 25.6 ± 3.06
Normal weight, % 18 < BMI ≤ 25 57 60 1.000 62
Overweight, % 25 < BMI ≤ 30 36 20 0.453 23
Obesity, % 30 < BMI ≤ 35 7 20 0.279 15
MRC scale 128.8 ± 14.9 145.4 ± 4.6 0.002
MIRS scale 12.4 ± 3.4 14.5 ± 1.0 0.063
Waist, cm 95.8 ± 10.2 97.2 ± 13.9 0.744
Hip, cm 98.5 ± 8.4 98.1 ± 11.5 0.912
Waist/hip 0.97 ± 0.05 0.99 ± 0.05 0.355
VO2, mL/kg/min 2.5 ± 0.5 2.6 ± 0.3 0.754
REE 1,351.7 ± 224.4 1,358.2 ± 280.7 0.942
EF, systolic, mm 5.99 ± 2.90 6.00 ± 1.15 0.994
Hepatic steatosis, % 57.1 70.0 0.269
Glucose, mg/dL 79.6 ± 9.9 91.8 ± 24.3 0.033
Insulin, microU/mL 10.7 ± 15.4 15.1 ± 11.7 0.422
HOMA-IR 2.09 ± 2.78 3.73 ± 3.33 0.136
Insulin resistance, % 14.3 60.0 0.010
Diabetes mellitus, % 3.5 40.0 0.012
HbA1c, % 5.29 ± 0.42 6.05 ± 1.38 0.014
Total-C, mg/dL 203.6 ± 39.8 218.7 ± 41.3 0.314
HDL-C, mg/dL 49.2 ± 11.6 52.6 ± 13.8 0.461
LDL-C, mg/dL 125.9 ± 34.1 137.6 ± 34.7 0.363
TG, mg/dL 145.9 ± 67.2 142.5 ± 94.7 0.902
Dyslipidemia, % 53.6 80.0 0.259
Testosterone, ng/dL 400.3 ± 147.6 344.2 ± 156.5 0.317
Free-T, ng/dL 7.33 ± 3.31 5.78 ± 1.79 0.168
17β-estradiol, pg/mL 46.4 ± 12.4 52.8 ± 11.5 0.180
SHBG, nmol/L 42.6 ± 17.0 42.4 ± 22.4 0.976
LH, mUI/L 8.5 ± 5.0 12.3 ± 5.8 0.057
FSH, mUI/L 17.6 ± 13.1 31.9 0.011
AMH, ng/mL 3.09 ± 3.42 0.64 ± 0.38 0.055
Inhibin B, pg/mL 90.67 ± 107.64 37.51 ± 24.54 0.181
Hypogonadism, % 25.0 50.0 0.235
BMI, body mass index; MRC, modified 5-point Medical Research Council scale; MIRS, muscular impairment rating scale; REE, resting energy expenditure; EF, epicardial fat; C, cholesterol; 
TG, triglycerides; free-T, free testosterone; SHBG, sex-hormone binding globuline; LH, luteinizing hormone; FSH, follicle-stimulating hormone; AMH, anti-Müllerian hormone.
*Comparison between DM1 and DM2 patients.
Bold means “statistically significant differences”.
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circulating levels of the myokine irisin in male DM patients in 
resting conditions and reported that plasma irisin was definitely 
decreased in both DM1 and DM2 patients compared with age-
matched male healthy controls. We investigated whether this 
reduction was related to muscle mass reduction or to an impaired 
muscle endocrine function in DM patients. The amount of irisin 
released from cultured myotubes derived from DM1 and DM2 
patients was unexpectedly similar to that detected in the medium 
of the myotubes derived from healthy donors, suggesting that the 
decreased plasma irisin levels likely reflect the skeletal muscle 
mass reduction rather than an impaired endocrine function of the 
muscle fibers. Indeed, irisin release from DM2 myotubes, whose 
patients had overt diabetes mellitus, was significantly higher 
than the amount released from DM1 non-diabetic myotubes. It 
is worth noting that myotubes from patients with type 2 diabetes 
expressed and secreted the highest levels of FNDC5 mRNA and 
irisin, respectively (27), resembling our finding in DM2 patients.
Although DM1 and DM2 have similar symptoms, they present 
dissimilarities making them clearly distinct diseases (28). Distal 
muscle weakness, facial weakness, and wasting are the core 
features in adult-onset DM1, while DM2 patients experience 
varying grip myotonia, thigh muscle stiffness, and muscle pain, 
as well as proximal muscle weakness (28). Besides myotonia and 
progressive muscle weakness, DM1 and DM2 are multisystemic 
syndromes and multiple metabolic functions are impaired. The 
analysis of the correlations between plasma irisin levels and 
anthropometric and metabolic parameters showed a distinct 
pattern in DM1 and DM2 patients, respectively, in DM1 patients, 
plasma irisin levels correlated negatively with oxygen consump-
tion and positively with insulin resistance, while in DM2 patients 
plasma irisin levels positively correlated with fat mass at arms 
and legs levels.
To discuss in detail our finding, it has to be considered that 
the main sources of circulating irisin are skeletal muscle, cardiac 
muscle (29) and white adipose tissue. First, despite in a cohort 
of sedentary middle-aged men, circulating irisin was positively 
associated with muscle mass and muscle strength (30), both 
DM1 and DM2 patients did not present any significant correla-
tion with muscle strength, muscle mass, or measures of disease 
severity. Second, knockdown of irisin in zebrafish decreased heart 
TaBle 3 | Significant correlations between plasma irisin levels and regional and 
total fat measured by DEXA in non-diabetic DM2 patients.
Parameters r P-value
Fat left arm 0.934 0.020
Fat right arm 0.976 0.005
Fat left leg 0.981 0.003
Fat right leg 0.991 0.001
Fat total body 0.830 0.041
TaBle 2 | Bone metabolism parameters and regional bone mineral densities 
evaluated by DEXA in DM1 and DM2 patients.
DM1 (n = 15) DM2 (n = 10) P-value
Bone metabolism parameters
Alb-corrected calcium, mg/dL 9.3 ± 0.4 9.3 ± 0.5 0.887
Phosphate, mg/dL 2.96 ± 0.58 3.29 ± 0.43 0.113
ALP, U/L 85.8 ± 35.2 64.8 ± 11.7 0.075
PTH, pg/mL 51.9 ± 41.5 57.2 ± 24.0 0.704
25OHD, ng/mL 16.4 ± 13.2 16.7 ± 10.4 0.960
Bone mineral density (BMD)
BMD mean arms, g/cm2 0.84 ± 0.08 0.76 ± 0.06 0.037
BMD mean ribs, g/cm2 0.77 ± 0.27 0.67 ± 0.09 0.390
BMD T spine, g/cm2 0.90 ± 0.28 0.91 ± 0.12 0.904
BMD L spine, g/cm2 1.14 ± 0.13 1.08 ± 0.14 0.391
BMD pelvis, g/cm2 1.27 ± 0.18 1.05 ± 0.08 0.008
BMD mean legs, g/cm2 1.28 ± 0.14 1.17 ± 0.08 0.069
BMD subtotal, g/cm2 1.10 ± 0.11 0.97 ± 0.06 0.014
BMD head, g/cm2 2.12 ± 0.49 1.88 ± 0.24 0.243
BMD total, g/cm2 1.21 ± 0.13 1.09 ± 0.06 0.039
Alb-corrected calcium, albumin corrected calcium; ALP, alkaline phosphatase activity; 
PTH, parathormone; 25OHD, 25 hydroxyvitamin D; T spine, thoracic spine; L spine, 
lumbar spine.
Bold means “statistically significant differences”.
FigUre 3 | Log2-transformed irisin levels positively correlated with total 
body fat (a) and with femoral neck T-score values in the whole series of DM2 
patients (n = 10) (B). Darker circles indicate DM2 patients with diabetes 
mellitus; continuous lines represent media values, dashed lines represent the 
95% confidence intervals.
FigUre 2 | Log2-transformed irisin levels positively correlated with log2 
serum insulin levels (a) and with log2 HOMA-IR values in non-diabetic DM1 
patients (n = 27) (B); continuous lines represent media values, dashed lines 
represent the 95% confidence intervals.
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rate, diastolic volume, and cardiac output (29). DM1 and DM2 
patients suffer from cardiac damage including abnormalities of 
the conduction system (31) and myocardial fibrosis (32, 33); 
though left ventricular mass was reduced in more than 60% of 
DM patients, in agreement with previous reports (33), plasma 
irisin did not correlate with left ventricular mass in both DM1 
and DM2 patients. Third, adipose tissue expresses the FNDC5 
gene and secretes irisin, but less than skeletal muscle (34) and 
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circulating irisin levels are positively associated with fat mass 
(20, 35–38), while negatively correlate with visceral adiposity 
in men (30). In our cohort, both DM1 and DM2 patients were 
characterized by a fat redistribution with increasing visceral fat 
mass, namely abdominal, liver, epicardial fat, while subcutaneous 
fat was reduced (16, 39). Similar to what reported in healthy sub-
jects, DM2 patients were characterized by a positive correlation 
between plasma irisin levels and the arms and legs fat measured by 
DEXA, while in DM1 patients, no correlation could be detected 
with the total body and regional fat mass as well as with visceral 
adiposity parameters, such as waist circumference, liver steatosis, 
and epicardial fat thickness.
Secreted irisin targets different tissues, mainly white adipose 
tissue and bone. In white adipose tissue, irisin induces browning, 
increases thermogenesis and energy expenditure. Oxygen con-
sumption is reduced in DM1 patients (16), and here we reported 
that it negatively correlated with plasma irisin levels, suggesting 
that irisin does not exert the expected thermogenic effect on adi-
pose tissue in DM1 patients. Bone is a recently described target 
of irisin, which plays a role in the control of bone mass. Irisin 
exerts its effect mainly on osteoblast lineage by enhancing dif-
ferentiation and activity of bone-forming cells (40). In humans, 
an inverse correlation between irisin levels and vertebral fragility 
fractures was described in overweight subjects, though BMD 
or lean mass were not correlated with irisin levels (41, 42). In 
both DM1 and DM2 patients, we observed positive correlations 
between plasma irisin and bone densities at pelvis and legs and at 
the femoral neck levels, respectively. Though the effect of diabetes 
could not be excluded in DM2 patients, this finding support the 
irisin-mediated cross talk between muscle and bone.
Finally, male DM1 and DM2 patients are metabolically 
unhealthy; in particular, they are hypogonadic, insulin resistant, 
and dyslipidemic. Hypogonadism frequently occurs in DM1 and 
DM2 patients (16), nonetheless plasma irisin levels were not cor-
related with parameters of gonadal hormone function. The finding 
is in agreement with experimental evidence reporting that orchi-
ectomy in rats does not affect serum irisin levels and testosterone 
treatment in orchiectomized rats does not affect muscle Fdnc5 
expression as well as serum irisin levels (43). Insulin resistance 
occurs in 25.0% of DM1, while overt diabetes was diagnosed in 
3.5% of DM1. Recently, in sedentary subjects and in non-diabetic 
adults, plasma irisin was found to positively correlate with insulin 
and HOMA-IR (44, 45). Similarly, we observed a positive correla-
tion between plasma irisin and insulin and HOMA-IR values in 
non-diabetic DM1 patients, while insulin resistance, which could 
be detected in 60.0% of non-diabetic DM2 patients, did not show 
any significant correlation with plasma irisin levels.
In conclusion, DM1 and DM2 male patients were characterized 
by reduced plasma irisin, which likely reflects muscle wasting as 
DM1 and DM2 muscle fibers conserve the ability to secrete irisin. 
Admittedly, though the series of DM1 and DM2 patients are well 
characterized about the endocrine and metabolic phenotype, the 
small sample size prevents to define the role of insulin resistance 
and hyperglycemia in regulating plasma irisin levels. However, 
though mainly based upon correlations, our results suggest 
that muscle endocrine function may be more impaired in DM1 
patients than in DM2 patients.
Based on recently reported results in mice (26), we speculate 
that replacement with recombinant irisin in young DM patients 
might improve their functional and metabolic profile; these pro-
spective view is also sustained by in vitro data showing that irisin 
stimulates myogenesis, as suggested by increased myocyte cell 
proliferation, higher myogenin/MYOG mRNA levels together 
with lower transcripts of myostatin/MSTN and dystrophin/DMD, 
and the muscle atrophy-related factors MuRF1 and MAFbx (5, 
46). Considering that during differentiation DM1 and DM2 
myotubes do not increase myogenin (47), treatment with recom-
binant irisin may be of interest in DM1 and DM2 management.
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